Company / Revenue
Edwards Lifesciences Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$6.1B
FY2025
5-year range
$4.5B / $6.1B
FY2021-FY2025
Trend
+11.5%
vs FY2024
Sector context
#35 of 156
Health Care
What the data says
Edwards Lifesciences's revenue of $6.1B is higher than 78% of companies in the Health Care sector (FY2025). Revenue has increased for 3 consecutive years, from $4.5B in FY2022 to $6.1B in FY2025.
Based on SEC 10-K filings.
$6.1B in FY2025 with a 5-year CAGR of +6.7%. Top quartile in the Health Care sector.
Improved from $5.2B to $6.1B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +10.8%
- 5-Year CAGR
- +6.7%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 156This company $6.1B Sector average $19.0B
▼
-68.1% below sector average
Key checks
Key Insights
- Edwards Lifesciences's revenue has grown for 3 consecutive years.
- 5-year CAGR of +6.7%, indicating consistent growth.
- In FY2025, revenue increased 11.5% year-over-year.
- Ranks #35 out of 156 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $6.1B | +11.5% |
| FY2024 | $5.4B | +4.0% |
| FY2023 | $5.2B | +17.2% |
| FY2022 | $4.5B | -14.7% |
| FY2021 | $5.2B | +19.3% |
| FY2020 | $4.4B | +0.9% |
| FY2019 | $4.3B | +16.8% |
| FY2018 | $3.7B | +8.4% |
| FY2017 | $3.4B | +15.9% |
| FY2016 | $3.0B | +18.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026